Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00990327 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
A Phase 3 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 3
- Development phase
- 863
- Enrollment target
NCT00990327 is a Phase 3 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 863 participants.
The verdict
NCT00990327, a Phase 3 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 863 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether apadenoson is as effective as adenosine when used as a pharmacological stress agent in myocardial SPECT-Imaging to detect defects in the supply of blood to the heart muscle (myocardial perfusion defects). The study will also look at whether apadenoson is better tolerated than adenosine when used in SPECT-MPI.
Interventions
- DRUG Apadenoson SPECT-MPI
- DRUG Adenosine SPECT-MPI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 863 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00990327
The ClinicalTrials.gov registry entry for NCT00990327 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 863 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apadenoson SPECT-MPI is the first listed.
NCT00990327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00990327 about?
NCT00990327 is a clinical study titled "Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI". The purpose of this study is to see whether apadenoson is as effective as adenosine when used as a pharmacological stress agent in myocardial SPECT-Imaging to detect defects in the supply of blood to the heart muscle (myocardial perfusion defects). The study will also look at whether apadenoson is b...
What is the current status of trial NCT00990327?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 863 participants. The study started on 2009-11. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00990327?
The interventions under investigation include: Apadenoson SPECT-MPI (DRUG), Adenosine SPECT-MPI (DRUG).
Who is sponsoring clinical trial NCT00990327?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.